Browsing by Subject "Parkinson's disease"
Now showing items 1-11 of 11
-
Body mass index and risk of Parkinson, Alzheimer, Dementia, and Dementia mortality: a systematic review and dose-response meta-analysis of cohort studies among 5 million participants
( Taylor and Francis Ltd. , 2022 , Article Review)Objective: Inconsistent results regarding the association between the Body Mass Index (BMI) and brain disorders have been reported. We performed this study to investigate the association between BMI and risk of Parkinson, ... -
Cardiovascular Risk Among Patients ≥ 65 Years of Age with Parkinson's Disease (From the National Inpatient Sample)
( Elsevier , 2020 , Article)In this study, we aimed to investigate the relationship between PD and vascular disease and risk factors using a nationally representative sample. The National Inpatient Sample (NIS) was queried for all patients aged ≥ 65 ... -
Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort
( Wiley , 2021 , Article)Background: Tangible efforts have been made to identify biomarkers for Parkinson's disease (PD) diagnosis and progression, with α-synuclein (α-syn) related biomarkers being at the forefront. Objectives: The objectives of ... -
A combined method of optimized learning vector quantization and neuro-fuzzy techniques for predicting unified Parkinson's disease rating scale using vocal features
( Elsevier B.V. , 2024 , Article)Parkinson's Disease (PD) is a common disorder of the central nervous system. The Unified Parkinson's Disease Rating Scale or UPDRS is commonly used to track PD symptom progression because it displays the presence and ... -
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis
( SAGE Publications Inc. , 2017 , Article Review)Objective: To summarize and evaluate the existing literature regarding medications to treat Parkinson's disease (PD) psychosis. Data Sources: MEDLINE (1946 to March 2017), EMBASE (1980 to March 2017), CINAHL (1982 to March ... -
Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils
( Elsevier , 2015 , Article)Compelling evidence indicates that α-synuclein (α-syn) aggregation plays a central role in the pathogenesis of Parkinson's disease (PD) and other synucleinopathies. Identification of compounds that inhibit or reverse the ... -
Lipid profile in Parkinson's disease: The potential role of brain-derived neurotrophic factor
( Elsevier , 2022 , Article)BackgroundParkinson's disease is a neurodegenerative disease manifested as increased tremor, bradykinesia, rigidity, and postural instability. Brain-derived neurotrophic factor (BDNF) is essential for neurocognitive function. ... -
Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity.
( FEBS PRESS , 2022 , Article)Nanobodies (Nbs), the single-domain antigen-binding fragments of dromedary heavy-chain antibodies (HCAb), are excellent candidates as therapeutic and diagnostic tools in synucleinopathies because of their small size, ... -
The role of amyloids in Alzheimer's and Parkinson's diseases
( Elsevier , 2021 , Article)With varying clinical symptoms, most neurodegenerative diseases are associated with abnormal loss of neurons. They share the same common pathogenic mechanisms involving misfolding and aggregation, and these visible aggregates ... -
The interactive effect of valence and context on reversal learning in individuals with Parkinson's disease
( Elsevier Ireland Ltd , 2019 , Article)Cognitive deficits in Parkinson’s disease (PD) have increasingly been recognized over the last decade and reversal learning in particular has received a great deal of attention. In a classical reversal-learning paradigm, ... -
Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
( Wiley , 2022 , Article)Background: The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has become the gold standard for evaluating different domains in Parkinson's disease (PD), and it is commonly used in clinical ...